Precigen, Inc. (NASDAQ:PGEN – Get Free Report) Director Nancy Agee bought 3,411 shares of Precigen stock in a transaction that occurred on Friday, August 21st. The stock was bought at an average cost of $7.23 per share, for a total transaction of $24,661.53. Following the purchase, the director owned 309,187 shares in the company, valued at $2,235,422.01. This represents a 1.12% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Precigen Price Performance
Shares of NASDAQ:PGEN opened at $7.19 on Friday. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. The business’s fifty day moving average price is $6.01 and its two-hundred day moving average price is $4.73. The stock has a market cap of $2.56 billion, a PE ratio of -6.91 and a beta of 1.02. Precigen, Inc. has a one year low of $2.99 and a one year high of $7.72.
Precigen (NASDAQ:PGEN – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company had revenue of $54.98 million during the quarter, compared to analysts’ expectations of $27.98 million. Precigen’s revenue for the quarter was up 6322.7% on a year-over-year basis. On average, analysts forecast that Precigen, Inc. will post 0.25 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Precigen
Hedge Funds Weigh In On Precigen
Institutional investors have recently added to or reduced their stakes in the business. State of Wyoming acquired a new stake in Precigen in the 1st quarter worth about $27,000. NBC Securities Inc. purchased a new stake in Precigen in the 4th quarter valued at about $38,000. Mason Investment Advisory Services Inc. acquired a new position in shares of Precigen during the 4th quarter valued at about $42,000. Abel Hall LLC acquired a new position in shares of Precigen during the 4th quarter valued at about $44,000. Finally, Royal Bank of Canada lifted its holdings in shares of Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,426 shares during the period. 33.51% of the stock is currently owned by institutional investors and hedge funds.
About Precigen
Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.
The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.
Read More
- Five stocks we like better than Precigen
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
